{
  "nctId": "NCT06473597",
  "briefTitle": "A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache",
  "officialTitle": "A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial",
  "protocolDocument": {
    "nctId": "NCT06473597",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2024-03-04",
    "uploadDate": "2024-06-19T12:13",
    "size": 184268,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06473597/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 80,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2024-09-01",
    "completionDate": "2026-12-31",
    "primaryCompletionDate": "2026-12-31",
    "firstSubmitDate": "2024-06-19",
    "firstPostDate": "2024-06-25"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adult ED patients age 18 to 65 years old\n* Acute headache\n* Initial Pain score of 5 on a standard 11- point (score 0 to 10) numeric rating scale\n* Patients will have to be awake, alert, and oriented to person, place, and time\n* Patients able to demonstrate understanding of the informed consent process and content.\n* Patients also will have to demonstrate ability to verbalize the nature of any adverse effects they might experience as well as to express their pain severity by using the NRS.\n\nExclusion Criteria:\n\n* Allergy to Rimegepant or Rizatriptan\n* Pregnancy and breastfeeding\n* Unstable vital signs\n* Inability to provide consent\n* Suspicion for disease process other than migraine (those requiring emergent brain imaging, with a temperature of 100.4 Â°F, with objective neurologic findings, secondary headache (an \"organic\" headache))\n* Ischemic coronary artery disease (angina pectoris, history of myocardial infarction), coronary artery vasospasm (including Prinzmetal's angina)\n* History of stroke or transient ischemic attack\n* Peripheral vascular disease\n* Ischemic bowel disease,\n* Uncontrolled hypertension\n* Use of another 5-HT1 agonist, ergotamine-containing medications, or ergot-type medications (methylsergide)\n* Hemiplegic or basilar migraine\n* Concurrent administration or recent discontinuation (within 2 weeks) of a MAO-A inhibitors\n* Current use of Rimegepant as a prophylactic\n* Severe Nausea and Vomiting\n* Severe headache requiring immediate intervention\n* Severe hepatic impairment\n* If taking any of the following medications (contraindications):\n\n  * Monoaminoxidaze (MAO) inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine)\n  * SSRI- Citalopram, Escitalopram, Sertraline\n  * Triptans: Sumatriptan, Zolmitriptan, Imigran\n  * Almotriptan.\n  * Cabergoline.\n  * Dihydroergotamine.\n  * Dihydroergotamine intranasal\n  * Eletriptan\n  * Ergoloid mesylates\n  * Ergotamine\n  * Frovatriptan\n  * Duloxetine\n  * Cyclobenzaprine\n  * Fluoxetine, velafaxine\n  * Trazodone\n  * Tramadol\n  * TCA: nortriptyline (Pamelor), amitriptyline, protriptyline\n  * Amphetamines: methamphetamine (Desoxyn), dextroamphetamine (Adderall, Adderall XR), dextroamphetamine (Dexedrine)\n  * azole antifungals ( ketoconazole, itraconazole)\n  * macrolide antibiotics (clarithromycin, erythromycin)\n  * rifamycins (such as rifampin, rifabutin)\n  * carbamazepine, phenytoin\n  * Cardiac Drug: amiodarone (Nexterone, Pacerone), quinidine, ranolazine (Aspruzyo Sprinkle), verapamil (Verelan, Verelan PM)",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Pain Score at 60 minutes",
        "description": "Change in Pain Score between baseline and 60 minutes. Pain score will be measured via validated an 11 point Likert Scale where 0 is no pain, 5 moderate pain and 10 very severe pain.",
        "timeFrame": "60 minutes"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Pain Score",
        "description": "Change in Pain Score between baseline and 120 minutes. Pain score will be measured via validated an 11 point Likert Scale where 0 is no pain, 5 moderate pain and 10 very severe pain.",
        "timeFrame": "120 minutes"
      },
      {
        "measure": "Rescue Analgesia at 60 minutes",
        "description": "Frequency of Rescue Analgesia at 60 minutes",
        "timeFrame": "60 minutes"
      },
      {
        "measure": "Rescue Analgesia at 120 minutes",
        "description": "Frequency of Rescue Analgesia at 120 minutes",
        "timeFrame": "120 minutes"
      },
      {
        "measure": "Percentage of Patients who Sustained Headache Freedom",
        "description": "Sustained headache freedom, defined as achieving a level of \"none\" on the severe, moderate, mild, and none scale within 2 hours of investigational medication administration and maintaining this level continuously for 24 hours without use of rescue medication.",
        "timeFrame": "24 hours"
      },
      {
        "measure": "Percentage of Patients Who Sustained Headache Relief",
        "description": "Sustained headache relief, defined as change within 2 hours of the patient's description of headache from severe or moderate to either mild or none without use of rescue medication, and maintaining this level of relief continuously for 24 hours.",
        "timeFrame": "24 hours"
      },
      {
        "measure": "Percentage of Patients who had Headache Relief In the ED",
        "description": "Headache relief in the ED, defined as change within 2 hours of the patient's description of headache from severe or moderate to either mild or none without the use of rescue medication",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Percentage of Patients with Headache Freedom in the ED",
        "description": "Headache freedom in the ED, defined as achieving a headache level of \"none\" within 2 hours without use of rescue medication",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Functional Status",
        "description": "Achieving a normal functional status by two hours",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Headache Medication Efficacy and Tolerability Perception by the Patient",
        "description": "The patient's overall assessment of efficacy and tolerability, expressed as a dichotomous response to the question \"Do you want to receive the same medication the next time you visit the ER with a migraine?\"",
        "timeFrame": "2 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 9,
      "otherCount": 0,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 84,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:53.731Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}